{"organizations": [], "uuid": "7ec042f7a01e14ff6f0244d1449a6c221e6e063e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-midatech-pharma-says-approval-of-i/brief-midatech-pharma-says-approval-of-investigational-new-drug-application-from-us-fda-to-conduct-study-of-mtx110-idUSFWN1PB0BP", "country": "US", "domain_rank": 408, "title": "BRIEF-Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-16T15:32:00.000+02:00", "replies_count": 0, "uuid": "7ec042f7a01e14ff6f0244d1449a6c221e6e063e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-midatech-pharma-says-approval-of-i/brief-midatech-pharma-says-approval-of-investigational-new-drug-application-from-us-fda-to-conduct-study-of-mtx110-idUSFWN1PB0BP", "ord_in_thread": 0, "title": "BRIEF-Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-midatech pharma", "sentiment": "negative"}, {"name": "midatech pharma plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Midatech Pharma Plc:\n* APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110\n* MTX110 IS AN INVESTIGATIONAL NANO-INCLUSION PRODUCT, FOR TREATMENT OF FATAL CHILDHOOD BRAIN CANCER DIPG Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T15:32:00.000+02:00", "crawled": "2018-01-17T20:10:45.005+02:00", "highlightTitle": ""}